Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$3.08 USD
+0.19 (6.57%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $3.07 -0.01 (-0.32%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ALLO 3.08 +0.19(6.57%)
Will ALLO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALLO
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Other News for ALLO
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Allogene Therapeutics initiates Phase 2 cema-cel trial